Apply for Funding

Screening Platform

Current Open RFP

GHIT Fund RFP Screening Platform 2025-002

The GHIT Fund launched the Screening Platform in early 2013 to facilitate the screening of compound libraries for the identification of novel compounds for malaria, tuberculosis, and selected NTDs.

The platform enables the screening of the Japanese compound libraries with PDPs via its established screening organization network, or leveraging Japanese screening technologies to conduct screening activities with the PDPs.

Following the COVID-19 pandemic, the GHIT Fund has expanded its disease scope by adding selected Viral Infectious Diseases for the Screening Platform. For more information on the target diseases, please refer to the Application Documents.

Partnership should include one of the following three leading PDPs:

- Medicines for Malaria Venture (MMV),

- Drugs for Neglected Diseases initiative (DNDi),

- TB Alliance.

RFP and Application Document

GHIT RFP Screening Platform 2025-002 Contact Form

Key RFP Milestone Dates

RFP Release	July 15 2025
Application Document	Submission deadline: 10:00 am (JST) on January 9, 2026 Submit via Editorial Manager® for Target Research Platform and Screening Platform ( https://www.editorialmanager.com/ghitfund_trp/ ) *Budget sheet template will be provided upon submission and the eligibility check of the Contact Form
Q&A (RFP related questions)	Submit questions to RFPResponse@ghitfund.org Email Subject Line: GHIT-RFP-Screening-2025-002_Questions
Notification of Results	To be notified after the submission of the Contact Form

See Past RFP

Investment Process

Applicants

Contact Form Submission

Interested applicants must complete the Contact Form and submit this to submit by email to RFPResponse@ghitfund.org

Management Team

Eligibility Assessment

For all applications received for the Screening Platform, the GHIT Management Team will conduct eligibility assessments with a focus on partnerships, scope of disease, intervention, and development stage.

Applicants

Discussion with PDPs on project scope

All applications should be submitted as a collaboration between a Japanese organization and one of the following three PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB). The details of screening activities will be discussed with representatives from each partner.

Board of Directors

Review

Each screening plan will be reviewed by Board Member.

Japanese organization-PDP-GHIT

Agreement

For approved projects, a three-way agreement (Japanese organization – PDP – GHIT) will be contracted, followed by the initiation of screening activities.

Management Team

Initiation of Monitoring and Evaluation

Once the agreement enters into effect, the GHIT Management Team will initiate the Monitoring and Evaluation process. The data and information regarding the project will be put into the system.

Management Team and Product Development Partners

Monitoring and Evaluation

To track the progress of each project, GHIT conducts progress updates twice a year. This enables us to keep track of the progress of investments and decide whether to continue, modify, or terminate the investment contingent upon milestone achievement. With this system, data pertaining to the progress of each project is gathered via an electronic system and the GHIT Management Team holds a conference with all product development partners based on the collected data prior to the meeting.